Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways with more than 100 staffers at a Massachusetts facility that will ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix. Read more here.

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.

GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season.

By Katherine Hamilton GSK received Food and Drug Administration approval for a prefilled syringe presentation of Singrix, a prevention vaccine for shingles.

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

GSK (NYSE:GSK) announced Thursday that the U.S. Food and Drug Administration (FDA) approved a new prefilled syringe presentation of its shingles vaccine, Shingrix, offering a convenient ...